A record of what Nuvama Analysis said publicly, with the source. Not advice.
Pending — not yet graded
“Maintained a 'Hold' rating on Sun Pharma with a target price of Rs 1,830. The brokerage expects FY26 to be investment-heavy due to promotions for Leqselvi and Unlocxyt and Phase II trials for GLO034, projecting revenue and PAT CAGR of 9% and 8% respectively over FY25–FY27. Margin outperformance was driven by an improved product mix and growth in Rest of World markets.”
Nuvama Analysis’s track record (trackable calls only): 161 graded calls · 95% CI 35–50%
Sun Pharmaceutical Industries Ltd.NeutralCalled 01 Aug 2025
This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.
Read the original articleSee Nuvama Analysis’s full track record